Vimian Group AB (publ) (VIMIAN.ST)
SEK 42.2
(2.93%)
SEK 42.2
(2.93%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 276.3 Million EUR | 54.56% |
| 2022 | 178.76 Million EUR | 42.72% |
| 2021 | 125.25 Million EUR | 122.7% |
| 2020 | 56.24 Million EUR | 1540.69% |
| 2019 | 3.42 Million EUR | -34.04% |
| 2018 | 5.19 Million EUR | 104040.0% |
| 2017 | -5000.00 EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 200.96 Million EUR | 50.8% |
| 2024 Q2 | 140.75 Million EUR | -48.63% |
| 2024 Q1 | 274.02 Million EUR | -0.83% |
| 2023 FY | 276.3 Million EUR | 54.56% |
| 2023 Q3 | 288.23 Million EUR | 0.01% |
| 2023 Q4 | 276.3 Million EUR | -4.14% |
| 2023 Q2 | 288.21 Million EUR | 49.73% |
| 2023 Q1 | 192.49 Million EUR | 7.68% |
| 2022 Q4 | 178.76 Million EUR | -27.22% |
| 2022 FY | 178.76 Million EUR | 42.72% |
| 2022 Q3 | 245.61 Million EUR | -3.25% |
| 2022 Q2 | 253.85 Million EUR | 28.23% |
| 2022 Q1 | 197.97 Million EUR | 58.06% |
| 2021 Q2 | 30.68 Million EUR | -38.94% |
| 2021 Q4 | 125.25 Million EUR | 183.31% |
| 2021 Q3 | 44.21 Million EUR | 44.09% |
| 2021 FY | 125.25 Million EUR | 122.7% |
| 2021 Q1 | 50.25 Million EUR | -10.66% |
| 2020 FY | 56.24 Million EUR | 1540.69% |
| 2020 Q1 | 12.04 Million EUR | 0.0% |
| 2020 Q4 | 56.24 Million EUR | 0.0% |
| 2019 FY | 3.42 Million EUR | -34.04% |
| 2018 FY | 5.19 Million EUR | 104040.0% |
| 2017 FY | -5000.00 EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AroCell AB (publ) | -50.72 Million SEK | 644.725% |
| Devyser Diagnostics AB (publ) | -188.09 Million SEK | 246.89% |
| Immunovia AB (publ) | -72.5 Million SEK | 481.094% |
| Prostatype Genomics AB (publ) | -2.61 Million SEK | 10666.004% |
| SenzaGen AB | -15.95 Million SEK | 1832.186% |
| Spermosens AB | 5.02 Million SEK | -5398.527% |